{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:00:48Z","timestamp":1793908848660,"version":"4.8.0"},"posted":{"date-parts":[[2026,5,28]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":14,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"funder":[{"name":"EDCTP2","award":["RIA2017S-2014 \u2013 PREVAC-UP"],"award-info":[{"award-number":["RIA2017S-2014 \u2013 PREVAC-UP"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["115854, EBOVAC1"],"award-info":[{"award-number":["115854, EBOVAC1"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]},{"award":["HHSN261201500003I"],"award-info":[{"award-number":["HHSN261201500003I"]}],"id":[{"id":"https:\/\/ror.org\/05mmhfh95","id-type":"ROR","asserted-by":"publisher"}]},{"award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"https:\/\/ror.org\/05mmhfh95","id-type":"ROR","asserted-by":"publisher"}]},{"id":[{"id":"https:\/\/ror.org\/02vjkv261","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The ongoing Bundibugyo virus disease (BDBV) outbreak in Central Africa highlights the absence of approved vaccines specifically targeting BDBV. Whether licensed Zaire ebolavirus (EBOV) vaccines induce cross-reactive immunity against BDBV remains largely unknown.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed an immunogenicity analysis using serum samples from participants enrolled in the PREVAC randomized clinical trial evaluating licensed Ebola vaccine strategies in West Africa. Samples collected at day 28 (D28) and month 3 (M3) following vaccination with rVSV\u0394G-ZEBOV-GP or Ad26.ZEBOV\/MVA-BN-Filo were assessed using a multiplex Luminex assay against glycoproteins from multiple filoviruses, including EBOV Kikwit, EBOV Mayinga, BDBV, Sudan virus, Reston virus, and Marburg virus.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 179 samples were analysed. Detectable cross-reactive antibody responses against BDBV were observed across vaccine groups, timepoints, and age categories. However, BDBV responses remained substantially lower than homologous EBOV responses. In rVSV recipients, median BDBV responses (net MFI) reached 282 (IQR 164\u2013644) at D28 compared with 1788 (832\u20133311) against the homologous Kikwit antigen. Similar patterns were observed following rVSV booster vaccination and Ad26.ZEBOV\/MVA-BN-Filo vaccination. The heterologous Ad26\/MVA regimen demonstrated increasing BDBV responses between D28 and M3.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Licensed EBOV vaccines induced detectable but quantitatively reduced cross-reactive antibody responses against BDBV. Although no direct assessment of vaccine efficacy against BDBV disease was possible, these findings support the plausibility of partial heterologous immunity following EBOV vaccination. In the absence of approved BDBV-specific vaccines, these data support the urgent evaluation of currently available Ebola vaccines during BDBV outbreaks and reinforce the importance of developing broadly protective pan-filovirus vaccines.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.05.27.26354223","type":"posted-content","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:55:19Z","timestamp":1780001719000},"source":"Crossref","is-referenced-by-count":6,"title":["Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines"],"prefix":"10.64898","author":[{"given":"Edouard","family":"Lhomme","sequence":"first","affiliation":[{"name":"Univ. Bordeaux, INSERM, Institut Bergoni\u00e9, CHU de Bordeaux, CIC 1401, Euclid\/F-CRIN clinical trials platform and U1219 BPH, Inria, Sistm, F-33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"French Institute for Health and Medical Research (INSERM), 75013 Paris, France"},{"name":"Vaccine Research Institute, Univ. Paris Est Cr\u00e9teil, Henri Mondor Hospital, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahidjo","family":"Ayouba","sequence":"additional","affiliation":[{"name":"Recherche Translationnelle Appliqu\u00e9e au VIH et aux Maladies Infectieuses, University of Montpellier, Institut de Recherche pour le D\u00e9veloppement, INSERM, 34090, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa","family":"Ben-Farhat","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, Institut Bergoni\u00e9, CHU de Bordeaux, CIC 1401, Euclid\/F-CRIN clinical trials platform, F-33000 Bordeaux, France"},{"name":"Univ. Bordeaux, INSERM, MART, UMS 54, F-33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Thaurignac","sequence":"additional","affiliation":[{"name":"Recherche Translationnelle Appliqu\u00e9e au VIH et aux Maladies Infectieuses, University of Montpellier, Institut de Recherche pour le D\u00e9veloppement, INSERM, 34090, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Roy","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, Institut Bergoni\u00e9, CHU de Bordeaux, CIC 1401, Euclid\/F-CRIN clinical trials platform, F-33000 Bordeaux, France"},{"name":"Univ. Bordeaux, INSERM, MART, UMS 54, F-33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoul Habib","family":"Beavogui","sequence":"additional","affiliation":[{"name":"Centre National de Formation et de Recherche en Sant\u00e9 Rurale de Maferinyah, Maferinyah, Guinea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seydou","family":"Doumbia","sequence":"additional","affiliation":[{"name":"University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kieh","sequence":"additional","affiliation":[{"name":"Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailah","family":"Leigh","sequence":"additional","affiliation":[{"name":"College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samba","family":"Sow","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 West Baltimore Street Baltimore, MD 21201-1509, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A","family":"Migueles","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA or under contract\/subcontract to NIAID"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Watson-Jones","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"ANRS Emerging Infectious Diseases, Paris, France"},{"name":"AP-HP, H\u00f4pital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales, Paris F-75018, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5235-3962","authenticated-orcid":false,"given":"Rodolphe","family":"Thi\u00e9baut","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, Institut Bergoni\u00e9, CHU de Bordeaux, CIC 1401, Euclid\/F-CRIN clinical trials platform and U1219 BPH, Inria, Sistm, F-33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Peeters","sequence":"additional","affiliation":[{"name":"Recherche Translationnelle Appliqu\u00e9e au VIH et aux Maladies Infectieuses, University of Montpellier, Institut de Recherche pour le D\u00e9veloppement, INSERM, 34090, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Richert","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, Institut Bergoni\u00e9, CHU de Bordeaux, CIC 1401, Euclid\/F-CRIN clinical trials platform and U1219 BPH, Inria, Sistm, F-33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Levy","sequence":"additional","affiliation":[{"name":"French Institute for Health and Medical Research (INSERM), 75013 Paris, France"},{"name":"Vaccine Research Institute, Univ. Paris Est Cr\u00e9teil, Henri Mondor Hospital, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026060100550759000_2026.05.27.26354223v1.1","unstructured":"Minist\u00e8re de la Sant\u00e9 Publique Hygi\u00e8ne et pr\u00e9voyance sociale [Internet]. [cited 2026 May 25];Available from: https:\/\/sante.gouv.cd\/epidemie\/ebola-bundibugyo-2026"},{"key":"2026060100550759000_2026.05.27.26354223v1.2","unstructured":"Ebola disease caused by Bundibugyo virus \u2013 Democratic Republic of the Congo [Internet]. [cited 2026 May 25];Available from: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2026-DON603"},{"key":"2026060100550759000_2026.05.27.26354223v1.3","unstructured":"Initial genomes from May 2026 Bundibugyo Virus Disease Outbreak in the Democratic Republic of the Congo and Uganda - Ebolavirus \/ Bundibugyo ebolavirus [Internet]. Virological. 2026 [cited 2026 May 24]; Available from: https:\/\/virological.org\/t\/initial-genomes-from-may-2026-bundibugyo-virus-disease-outbreak-in-the-democratic-republic-of-the-congo-and-uganda\/1032"},{"key":"2026060100550759000_2026.05.27.26354223v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0602-4"},{"key":"2026060100550759000_2026.05.27.26354223v1.5","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir350"},{"issue":"12","key":"2026060100550759000_2026.05.27.26354223v1.6","doi-asserted-by":"crossref","first-page":"e2600","DOI":"10.1371\/journal.pntd.0002600","article-title":"Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus","volume":"7","year":"2013","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"792","key":"2026060100550759000_2026.05.27.26354223v1.7","doi-asserted-by":"crossref","first-page":"eadq2496","DOI":"10.1126\/scitranslmed.adq2496","article-title":"Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses","volume":"17","year":"2025","journal-title":"Sci Transl Med"},{"issue":"26","key":"2026060100550759000_2026.05.27.26354223v1.8","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2200072","article-title":"Randomized Trial of Vaccines for Zaire Ebola Virus Disease","volume":"387","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2026060100550759000_2026.05.27.26354223v1.9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13063-021-05035-9","article-title":"Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries","volume":"22","year":"2021","journal-title":"Trials"},{"key":"2026060100550759000_2026.05.27.26354223v1.10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01979-16"},{"key":"2026060100550759000_2026.05.27.26354223v1.11","unstructured":"Berry IM , Ben Farhat S , Callier V , et al. Comparison of Four Assays That Measure Antibodies to Ebola Virus Glycoprotein. 2026;"},{"issue":"1","key":"2026060100550759000_2026.05.27.26354223v1.12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41541-020-00261-9","article-title":"Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate","volume":"5","year":"2020","journal-title":"npj Vaccines"},{"key":"2026060100550759000_2026.05.27.26354223v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2129"},{"key":"2026060100550759000_2026.05.27.26354223v1.14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004582"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.05.27.26354223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:55:16Z","timestamp":1780300516000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.05.27.26354223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":14,"URL":"https:\/\/doi.org\/10.64898\/2026.05.27.26354223","relation":{},"subject":[],"published":{"date-parts":[[2026,5,28]]},"subtype":"preprint"}}